The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes - Scharnagl, H; Stojakovic, T; Winkler, K; Rosinger, S; März, W; Boehm, B O (Exp Clin Endocrinol Diabetes, 2007)